申请人:Takasago International Corporation
公开号:US05712388A1
公开(公告)日:1998-01-27
To prepare the compound (1'R,3S)-3-(1'-tri-substituted silyloxyethyl)azetidin-2-one, (2S,3R)-2-aminomethyl-3-hydroxybutyric acid is reacted with an alcohol in the presence of at least one compound chosen from the group consisting of thionyl chloride, hydrogen chloride and p-toluene sulfonic acid, thereby obtaining a salt of the corresponding ester. The salt is reacted with a tri-substituted silane in the presence of a metallic catalyst, thereby protecting the hydroxy group of the ester and then reacted with a base, thereby obtaining an ester of (2S,3R)-2-aminomethyl-3-(tri-substituted silyloxy)butyric acid. Subsequently, the ester is transformed into lactam in the presence of a Grignard reagent or a metal amide, thereby obtaining (1'R,3S)-3-(1'-tri-substituted silyloxyethyl)azetidin-2-one. This compound provides a useful base for preparing .beta.-lactam type antimicrobial agents such as carbapenem type agents.
为制备化合物(1'R,3S)-3-(1'-三取代硅氧基乙基)吖啶-2-酮,(2S,3R)-2-氨甲基-3-羟基丁酸与一种来自硫酰氯、氯化氢和对甲苯磺酸组合的至少一种化合物在醇的存在下发生反应,从而获得相应酯的盐。该盐在金属催化剂的存在下与三取代硅烷发生反应,从而保护酯的羟基,然后与碱发生反应,从而获得(2S,3R)-2-氨甲基-3-(三取代硅氧基)丁酸酯。随后,在格氏试剂或金属酰胺的存在下将酯转化为内酰胺,从而获得(1'R,3S)-3-(1'-三取代硅氧基乙基)吖啶-2-酮。该化合物为制备β-内酰胺类抗菌药物如头孢菌素类药物提供了有用的基础。